Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: A critical review of the current literature

European Urology

Volumn 64, Issue 4, 2013, Pages 624-638

  Rink, Michael ^a   Babjuk, Marko ^b   Catto, James W F ^c   Jichlinski, Patrice ^d   Shariat, Shahrokh F ^e   Stenzl, Arnulf ^f   Stepp, Herbert ^g   Zaak, Dirk ^h   Witjes, J Alfred ⁱ  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h Radiation Oncology   (Germany)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Hexyl aminolevulinate; Non muscle invasive bladder cancer; Photodynamic diagnosis; Recurrence free survival; Tumour detection; Urothelial cancer

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER;

BLADDER TUMOR; CANCER DIAGNOSIS; CANCER RECURRENCE; CARCINOMA IN SITU; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; DISEASE COURSE; FOLLOW UP; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PAPILLOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; URINE CYTOLOGY;

COST EFFECTIVENESS; HEXYL AMINOLEVULINATE; NON-MUSCLE-INVASIVE BLADDER CANCER; PHOTODYNAMIC DIAGNOSIS; RECURRENCE-FREE SURVIVAL; TUMOUR DETECTION; UROTHELIAL CANCER;

AMINOLEVULINIC ACID; COST-BENEFIT ANALYSIS; CYSTECTOMY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; HEALTH CARE COSTS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; PHOTOSENSITIZING AGENTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84883795088     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.07.007     Document Type: Review

References (70)

1. European Cancer Observatory. International Agency for Research on Cancer Web site. http://eu-cancer.iarc.fr.
2. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
3. A. Pawinski, R. Sylvester, and K.H. Kurth A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer J Urol 156 1996 1934 1940 discussion 1940-1
4. F. Thomas, A.P. Noon, N. Rubin, J.R. Goepel, and J.W. Catto Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer Eur Urol 63 2013 145 154
5. K.D. Sievert, B. Amend, and U. Nagele Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295 300
6. M. Rink, E.K. Cha, and D. Green Biomolecular predictors of urothelial cancer behavior and treatment outcomes Curr Urol Rep 13 2012 122 135
7. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
8. J.A. Witjes, J.P. Redorta, and D. Jacqmin Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations Eur Urol 57 2010 607 614
9. P. Jichlinski, and D. Jacqmin Photodynamic diagnosis in non-muscle-invasive bladder cancer Eur Urol Suppl 7 2008 529 535
10. S. Collaud, A. Juzeniene, J. Moan, and N. Lange On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation Curr Med Chem Anticancer Agents 4 2004 301 316
11. D. Jocham, H. Stepp, and R. Waidelich Photodynamic diagnosis in urology: state-of-the-art Eur Urol 53 2008 1138 1150
12. D.I. Daniltchenko, C.R. Riedl, and M.D. Sachs Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study J Urol 174 2005 2129 2133 discussion 2133
13. M. Kriegmair, D. Zaak, and H. Stepp Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy Eur Urol 36 1999 386 392
14. C.R. Riedl, D. Daniltchenko, F. Koenig, R. Simak, S.A. Loening, and H. Pflueger Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer J Urol 165 2001 1121 1123
15. D. Zaak, M. Kriegmair, and H. Stepp Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies Urology 57 2001 690 694
16. Y. Fradet, H.B. Grossman, L. Gomella PC B302/01 Study Group A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study J Urol 178 2007 68 73 discussion 73
17. M.C. Schumacher, S. Holmang, T. Davidsson, B. Friedrich, J. Pedersen, and N.P. Wiklund Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study Eur Urol 57 2010 293 299
18. A. Stenzl, H. Penkoff, and E. Dajc-Sommerer Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial Cancer 117 2011 938 947
19. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 8 2010 336 341
20. D. Moher, K.F. Schulz, and D.G. Altman The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials Lancet 357 2001 1191 1194
21. P.M. Bossuyt, J.B. Reitsma, D.E. Bruns Standards for Reporting of Diagnostic Accuracy Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative BMJ 326 2003 41 44
22. M. Babjuk, V. Soukup, R. Petrik, M. Jirsa, and J. Dvoracek 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer BJU Int 96 2005 798 802
23. M. Burger, C.G. Stief, and D. Zaak Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors Urology 74 2009 1282 1286
24. M. Burger, D. Zaak, and C.G. Stief Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis Eur Urol 52 2007 142 147
25. R. Colombo, R. Naspro, and P. Bellinzoni Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder Ther Clin Risk Manag 3 2007 1003 1007
26. M.A. D'Hallewin, H. Vanherzeele, and L. Baert Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid Am J Clin Oncol 21 1998 223 225
27. C. De Dominicis, M. Liberti, and G. Perugia Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity Urology 57 2001 1059 1062
28. S. Denzinger, M. Burger, and B. Walter Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study Urology 69 2007 675 679
29. S. Denzinger, W.F. Wieland, W. Otto, T. Filbeck, R. Knuechel, and M. Burger Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study BJU Int 101 2008 566 569
30. A. Ehsan, F. Sommer, G. Haupt, and U. Engelmann Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid Urol Int 67 2001 298 304
31. T. Filbeck, U. Pichlmeier, R. Knuechel, W.F. Wieland, and W. Roessler Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology 60 2002 1025 1028
32. T. Filbeck, U. Pichlmeier, R. Knuechel, W.F. Wieland, and W. Roessler Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors J Urol 168 2002 67 71
33. T. Filbeck, W. Roessler, R. Knuechel, M. Straub, H.J. Kiel, and W.F. Wieland Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid J Endourol 13 1999 117 121
34. T. Filbeck, W. Roessler, R. Knuechel, M. Straub, H.J. Kiel, and W.F. Wieland 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors Urology 53 1999 77 81
35. B. Geavlete, M. Jecu, R. Multescu, D. Georgescu, and P. Geavlete HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer - re-TURBT recurrence rates in a prospective, randomized study Urology 76 2010 664 669
36. B. Geavlete, R. Multescu, D. Georgescu, M. Jecu, F. Stanescu, and P. Geavlete Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 109 2012 549 556
37. M.C. Grimbergen, C.F. van Swol, T.G. Jonges, T.A. Boon, and R.J. van Moorselaar Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy Eur Urol 44 2003 51 56
38. H.B. Grossman, L. Gomella, Y. Fradet PC B302/01 Study Group A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer J Urol 178 2007 62 67
39. H.B. Grossman, A. Stenzl, and Y. Fradet Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
40. G.G. Hermann, K. Mogensen, S. Carlsson, N. Marcussen, and S. Duun Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study BJU Int 108 2011 E297 E303
41. E. Hungerhuber, H. Stepp, and M. Kriegmair Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder Urology 69 2007 260 264
42. S.S. Jeon, I. Kang, J.H. Hong, H.Y. Choi, and S.E. Chai Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms J Endourol 15 2001 753 759
43. P. Jichlinski, L. Guillou, and S.J. Karlsen Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study J Urol 170 2003 226 229
44. D. Jocham, F. Witjes, and S. Wagner Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study J Urol 174 2005 862 866 discussion 866
45. A. Karl, S. Tritschler, and P. Stanislaus Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy? BJU Int 103 2009 484 487
46. F. Koenig, F.J. McGovern, R. Larne, H. Enquist, K.T. Schomacker, and T.F. Deutsch Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid BJU Int 83 1999 129 135
47. M. Kriegmair, R. Baumgartner, R. Knuchel, H. Stepp, F. Hofstädter, and A. Hofstetter Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence J Urol 155 1996 105 109 discussion 109-10
48. M. Kriegmair, R. Baumgartner, and R. Knuechel Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid Urology 44 1994 836 841
49. M. Kriegmair, D. Zaak, and K.H. Rothenberger Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy J Urol 168 2002 475 478
50. W. Loidl, J. Schmidbauer, M. Susani, and M. Marberger Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 47 2005 323 326
51. E.R. Ray, K. Chatterton, and M.S. Khan Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin BJU Int 105 2010 789 794
52. E.R. Ray, K. Chatterton, M.S. Khan, K. Thomas, A. Chandra, and T.S. O'Brien Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology BJU Int 103 2009 1363 1367
53. E.R. Ray, K. Chatterton, K. Thomas, M.S. Khan, A. Chandra, and T.S. O'Brien Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer J Endourol 23 2009 983 988
54. C.R. Riedl, E. Plas, and H. Pfluger Fluorescence detection of bladder tumors with 5-amino-levulinic acid J Endourol 13 1999 755 759
55. J. Schmidbauer, F. Witjes, N. Schmeller, R. Donat, M. Susani, M. Marberger Hexvix PCB301/01 Study Group Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy J Urol 171 2004 135 138
56. A. Stenzl, M. Burger, and Y. Fradet Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer J Urol 184 2010 1907 1913
57. J.A. Witjes, P.M. Moonen, and A.G. van der Heijden Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study Eur Urol 47 2005 319 322
58. D. Zaak, E. Hungerhuber, and P. Schneede Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions Cancer 95 2002 1234 1238
59. G. Mowatt, J. N'Dow, L. Vale Aberdeen Technology Assessment Review (TAR) Grou Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis Int J Technol Assess Health Care 27 2011 3 10
60. P. Shen, J. Yang, and W. Wei Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis BJU Int 110 2012 E209 E215
61. P. Jichlinski, M. Forrer, and J. Mizeret Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results Lasers Surg Med 20 1997 402 408
62. A. Marti, P. Jichlinski, and N. Lange Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer J Urol 170 2003 428 432
63. G.G. Hermann, K. Mogensen, B.G. Toft, A. Glenthoj, and H.M. Pedersen Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies Scand J Urol Nephrol 46 2012 31 36
64. M.D. Shelley, T.J. Wilt, J. Court, B. Coles, H. Kynaston, and M.D. Mason Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 2004 485 490
65. R.O. Draga, M.C. Grimbergen, E.T. Kok, T.N. Jonges, C.F. van Swol, and J.L. Bosch Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy Eur Urol 57 2010 655 660
66. M. Rink, F.K. Chun, and T.F. Chromecki Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies [in German] Urologe A 51 2012 820 828
67. D. Zaak, W.F. Wieland, C.G. Stief, and M. Burger Routine use of photodynamic diagnosis of bladder cancer: practical and economic issues Eur Urol Suppl 7 2008 536 541
68. A. Stenzl, L. Höltl, and G. Bartsch Fluorescence assisted transurethral resection of bladder tumours: is it cost effective? Eur Urol 39 2001 31
69. A. Naselli, C. Introini, and L. Timossi A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence Eur Urol 61 2012 908 913
70. C. Zheng, Y. Lv, Q. Zhong, R. Wang, and Q. Jiang Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis BJU Int 110 2012 E680 E687